It has been acknowledged that examination of serum CEA and CA19-9 does not have sufficient capability for early identification of colon cancer due to their low abnormality rates in stage I (12-19% and 8%, respectively) and stage II patients (47-49% and 17%, respectively) [20],[21]. This evidence concerns the gene CEACAM5 and malignant colon neoplasm.